Seeking Alpha

Wedbush sees big upside for Relypsa

  • Shares of recently public Relypsa (RLYP +7.2%) are up sharply in morning trading.
  • Wedbush is initiating at Outperform, citing Patiromer potential.
  • The hyperkalemia treatment "has shown a potentially best-in-class profile [and] can achieve peak annual sales of about $1.4B in the U.S," analyst Liana Moussatos says.
  • Price target is $34, representing upside of 70% from Monday's close.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector